Nuvation Bio Inc. (NYSE: NUVB) is a Healthcare company (Biotechnology) with a market capitalization of $1.4B. The Maz Rating grades it against the other companies in its sector.
Nuvation Bio Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.90, Nuvation Bio Inc. trades at 6.8x sales and 6.0x book value. Over the last twelve months it generated about $201M of revenue and a net loss of $139M. It runs a gross margin of 90.6%, an operating margin of -61.2% and a net margin of -67.4%. It shows return on equity of -49.1%, return on invested capital of -17.6% and a free cash flow yield of -7.9%. On the balance sheet: a debt-to-equity ratio of 2.05 and a current ratio of 7.45. Over the past 52 weeks the share price ranged from $3.79 to $9.75, with a beta of 1.73.
Nuvation Bio Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 8 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Nuvation Bio Inc. (NUVB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 23.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 34.8% / 30% · Interest income / Revenue 13.7% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 23.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 34.8% / 33% · Receivables / Mkt Cap (36m) 2.11% / 49% · Interest income / Revenue 13.7% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 23.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 34.8% / 33.33% · Receivables / Mkt Cap (24m) 2.11% / 33.33% · Interest income / Revenue 13.7% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 26.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 87.5% / 33.33% · Receivables / Avg Assets (4Q) 4.30% / 33.33% · Interest income / Revenue 13.7% / 5% | Fail |
| FTSE | Debt / Total Assets 58.3% / 33.33% · (Cash+ST Inv) / Total Assets 85.2% / 33.33% · (Cash+Recv) / Total Assets 90.4% / 33.33% · Interest income / Revenue 13.7% / 5% | Fail |
No. As of September 2026, Nuvation Bio Inc. (NUVB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Nuvation Bio Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 13.7% of each dividend: Nuvation Bio Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.